1 / 9

Erythropoietin

Erythropoietin. Justin Tuwatananurak T-RAP Fall 2011. Background Info. First identified in the early 1900s when Paul Carnot observed that rabbits subject to hemotropic factor hemopoeitin (later renamed erythropoietin) exhibited increased RBC production.

sveta
Télécharger la présentation

Erythropoietin

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Erythropoietin Justin Tuwatananurak T-RAP Fall 2011

  2. Background Info • First identified in the early 1900s when Paul Carnot observed that rabbits subject to hemotropic factor hemopoeitin (later renamed erythropoietin) exhibited increased RBC production. • Peptide hormone (glycoprotein); functions as a cytokine for RBC precursors located in bone marrow. • Was first synthesized in 1985 at Columbia University, and a synthetic from of erythropoietin (Epo) was approved by the FDA in 1989.

  3. Function • Primary effect: Increase hematocrit, or % of RBCs in blood. • Cooperates with growth factors (SCIF, GM-CSF, 1L-3, and IGF-1) to stimulate RBC production. • Prevent erythrocytes from undergoing apoptosis. • Also can promote angiogenesis, increase blood pressure, and induce smooth muscle proliferation. • Increase iron absorption by suppressing hepcidin.

  4. Regulation

  5. Medical applications • Generally used to treat patients with anemia. • Chronic kidney disease • Myelodysplasia resulting from cancer treatment • Administered via injections or IV drip • Compatible with Jehovah’s Witness religious doctrine, since it’s not a blood transfusion.

  6. Blood Doping • Epo can be used to improve athletic endurance by increasing RBC count, allowing for higher blood oxygenation and O2 transport to the muscles. • Has been banned since the early 1990’s as a PED. • Can test for blood doping by checking the urine for recombinant Epo, but detection is still difficult.

  7. Potential side effects • Increased hematocrit may lead to blood thickening • Thrombosis • Stroke • Hypertension • Various Drug Interactions • Lenalidomide: increased risk of thrombosis • Cyclosporine: additive effects on increasing blood pressure • Increased risk of tumor growth in chemo patients

  8. Recent developments • 2007: FDA strengthens safety information for erythropoesis-stimulating agents • Recommends using smallest possible dose to avoid blood tranfusions, and to monitor hemoglobin levels • Affymax, Inc. developing peginesatide, a once-monthly erythropoiesis-stimulating agent. • Fibrogen currently developing HIF-PHIs, which are taken orally to stimulate endogenous Epo production.

  9. References • FDA • http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108864.htm • MarketWatch • http://www.marketwatch.com/story/affymaxr-receives-10-million-milestone-payment-for-fda-filing-of-new-drug-application-for-hematidetmpeginesatide-2011-08-10?reflink=MW_news_stmp • PubMed: Epoetin Alpha Injection • http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0000913/ • Fibrogen: HIF-PHI therapy • http://www.fibrogen.com/HIF_PHI_Therapy • R. Niesvizky, A. Spencer, M. Wang, D. Weber, C. Chen, M. A. Dimopoulos, Z. Yu, Z. Yu, R. Delap, J. Zeldis, R. D. Knight. Increased risk of thrombosis with lenalidomide in combination with dexamethasone and erythropoeitin. Journal of Clinical Oncology (2006) 24(18): 7506.

More Related